N=291 | |
Age | 35.0 (21.0) |
Disease duration prior to IFX | 89.95 (157.2) |
Montreal classification for Crohn’s, Age at diagnosis (years) | |
A1 | 58 (19.9) |
A2 | 197 (67.7) |
A3 | 36 (12.4) |
Montreal classification for Crohn’s, Location | |
L1 | 41 (14.1) |
L2 | 72 (24.7) |
L3 | 177 (60.8) |
+L4 | 59 (20.4) |
+Perianal | 138 (47.4) |
Montreal classification for Crohn’s, Behaviour | |
B1 | 76 (26.1) |
B2 | 45 (15.5) |
B3 | 170 (58.4) |
Indication for IFX | |
Luminal CD | 184 (63.2) |
Perianal CD | 55 (18.9) |
Luminal+perianal CD | 52 (17.9) |
Previous exposure to biologic, n (%) | 24 (8.2) |
Previous intestinal surgery, n (%) | 125 (43.0) |
Era of IFX initiation, n (%) | |
Pre-TDM | 161 (55.3) |
Post-TDM | 130 (44.7) |
Patients tested for TDM, n (%) | 238 (81.8) |
Median (range) number of TDMs per patient | 2 (0–8) |
Interval from 1st infusion to 1st TDM (months) | 12.5 (30.2) |
Undetectable levels episode, n (%) | 95 (40.1) |
ATI episode, n (%) | 76 (31.9) |
Dose intensification episode, n (%) | 62 (21.3) |
Patients discontinued IFX due to SLR or SAE, n (%) | 109 (37.5) |
Abdominal surgery after IFX initiation, n (%) | 44 (15.1) |
Duration of overall follow-up (months) | 44.7 (40.3) |
All values represent median (IQR) unless otherwise indicated. Time and duration is expressed in months.
ATI, antibodies to infliximab; CD, Crohn’s disease; IFX, infliximab; SAE, serious adverse event; SLR, secondary loss of response; TDM, therapeutic drug monitoring.